Anthrax Immune Globulin (human)
Anthrax Immune Globulin (human) Uses, Dosage, Side Effects, Food Interaction and all others data.
Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and edema toxins. This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.
| Trade Name | Anthrax Immune Globulin (human) |
| Generic | Anthrax immune globulin human |
| Anthrax immune globulin human Other Names | Anthrax immune globulin (human), Anthrax immune globulin human, Anthrax immunoglobulin (human), Bacillus anthracis immune globulin human |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Anthrax Immune Globulin (human) is an immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents.
Anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.
Anthrax Immune Globulin (human) is also used to associated treatment for these conditions: Inhaled anthrax caused by Bacillus anthracis
How Anthrax Immune Globulin (human) works
Polyclonal anthrax immune globulin is a passive immunizing agent that neutralizes anthrax toxin by binding to Protective Antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.
Toxicity
The most common adverse reactions to Anthrasil observed in >5% of healthy volunteers in clinical trials were headache, infusion site pain and swelling, nausea, and back pain.
Food Interaction
No interactions found.Volume of Distribution
5714.8 mL
Elimination Route
Peak levels were reached immediately after infusion and then declined over the duration of study (84 days). Mean activity remained above the lower limit of quantitation (5 milliunits per mL) over the entire 84-day post-dose period for the three doses studied. Cmax was found to be 83.0 mU/mL while Tmax was found to be 0.116 days.
Half Life
24.3 days
Clearance
174.2 mL/day
Innovators Monograph
You find simplified version here Anthrax Immune Globulin (human)
